BioNTech SE   (NASDAQ:BNTX)

178.03    $-17.97   -9.17%
Market open   Tuesday, Jan 18 2022 11:15 AM

BioNTech SE Chart

BNTX Stock Price Today

BioNTech SE (BNTX) stock plummeted over -9.17% intraday to trade at $178.03 a share on NASDAQ. The stock opened with a loss of -6.49% at $183.27 and touched an intraday high of $206.24, rising 5.22% against the last close of $196.00. The stock went to a low of $194.61 during the session.

Stock Snapshot

196.00
Prev. Close
183.27
Open
49.23B
Market Cap
244.37M
Number of Shares
194.61
day Low
206.24
Day High
178.03
5.53
P/E ratio
1.00%
Free Float in %
31.84
EPS (TTM)
40.83
Book Value per Share
10.92
Cash Flow per Share
1.61M
Volume

BioNTech SE Historical Data

DateOpenCloseDaily HighDaily LowVolume
2022-01-14$195.56$196.00$206.24$194.612,861,700
2022-01-13$217.09$202.99$220.20$202.862,252,700
2022-01-12$216.78$220.87$221.57$213.741,806,600
2022-01-11$222.93$215.80$224.23$213.022,614,100
2022-01-10$204.45$230.00$230.35$201.553,737,700
2022-01-07$213.70$211.84$217.73$209.271,200,600
2022-01-06$214.48$214.74$217.50$198.002,753,800
2022-01-05$230.47$211.43$230.59$211.033,098,300
2022-01-04$231.81$224.09$233.52$220.003,403,800
2022-01-03$253.87$231.85$256.14$231.503,776,400
2021-12-31$253.56$257.80$263.95$251.371,155,000

Contact Details

An der Goldgrube 12
Mainz 55131
Germany
https://www.biontech.de
49 6131 9084 0

About Company

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Frequently Asked Questions

What is the current BioNTech SE (BNTX) stock price?

BioNTech SE (NASDAQ: BNTX) stock price is $178.03 as of the last check on Tuesday, Jan 18 2022. During the trading session, BNTX stock reached the peak price of $206.24 while $194.61 was the lowest point it dropped to.

BNTX's industry and sector of operation?

The NASDAQ listed BNTX is part of Biotechnology industry that operates in the broader Healthcare sector. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

Who are the executives of BNTX?

Prof. Ugur Sahin M.D.
Co-Founder, CEO & Member of Management Board

Dr. Sierk Poetting Ph.D.
CFO, MD, COO & Member of Management Board

Mr. Sean Marett
Chief Bus. Officer, Chief Commercial Officer & Member of Management Board

Dr. Ozlem Tureci M.D.
Chief Medical Officer & Member of Management Board


What is the BNTX stock price today?

BNTX stock is trading at $178.03 today, which is $-17.97 or -9.17% lower than its previous close of $196.00. BNTX's current trading price is -61.63% lower than its 52-week high of $464.00 where as its distance from 52-week low of $90.29 is 97.18%.

How many employees does BNTX have?

Number of BNTX employees currently stands at 1800. BNTX operates from An der Goldgrube 12 Mainz 55131 Germany.

Link for BNTX official website?


How do I contact BNTX?

BNTX could be contacted at An der Goldgrube 12 Mainz 55131 Germany, or at phone # 49 6131 9084 0 and can also be accessed through its website: https://www.biontech.de

How many shares of BNTX are traded daily?

BNTX stock volume so far today is 1.61M shares while in the previous session number of BNTX shares traded was 2.86M. The average number of BNTX shares traded daily for last 3 months was 3.32M.

How much did BNTX change today?

The percentage change in BNTX stock occurred in the recent session was -9.17% while the dollar amount for the price change in BNTX stock was $-17.97.

What price range BNTX stock been trading in?

In the recent session, the day high for BNTX stock was $206.24 while the low for BNTX stock touched on the day was $194.61.

What is the market cap of BNTX currently?

The market value of BNTX currently stands at $49.23B with its latest stock price at $178.03 and 244.37M of its shares outstanding.